Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02346084 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults
A Phase 1 study, sponsored by International Partnership for Microbicides.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02346084 is a Phase 1 study that has completed, run by International Partnership for Microbicides. The registered enrollment target is 19 participants.
The verdict
NCT02346084, a Phase 1 study, has completed, sponsored by International Partnership for Microbicides.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety, acceptability, and PK/PD profile of maraviroc gel following rectal and vaginal administration. The study also includes oral exposure to maraviroc.
Interventions
- DRUG Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02346084
The ClinicalTrials.gov registry entry for NCT02346084 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International Partnership for Microbicides, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV) is the first listed.
NCT02346084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02346084 about?
NCT02346084 is a clinical study titled "Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults". The purpose of the study is to evaluate the safety, acceptability, and PK/PD profile of maraviroc gel following rectal and vaginal administration. The study also includes oral exposure to maraviroc.
What is the current status of trial NCT02346084?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2015-01. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02346084?
The interventions under investigation include: Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV) (DRUG).
Who is sponsoring clinical trial NCT02346084?
This trial is sponsored by International Partnership for Microbicides, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.